Elderly Men May Need Higher Rituximab Dose for DLBCL

Share this content:

the Cancer Therapy Advisor take:

Survival for elderly men with diffuse large B-cell lymphoma (DLBCL) who are receiving standard therapy appears to be lower than that of elderly women on the same treatment regimen. According to research presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, this difference in survival may be due to sex-related differences in clearance rate of rituximab.

 

Elderly men, for example, have faster rituximab clearance rates than elderly women, thereby shortening their exposure time to the treatment.

 

Researchers found that boosting the rituximab dose from 375 mg/m2 to 500 mg/m2 improved progression-free survival (PFS) and overall survival (OS) so that it was comparable to that seen in elderly women with DLBCL. Both groups received treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-14).

 

For this study, dubbed SEXIE-R-CHOP 14, the researchers randomly assigned 268 evaluable patients aged 60 to 80 years receive treatment. A total of 148 men received rituximab 500 mg/m2 instead of 375 mg/m2 and 120 women received rituximab 375 mg/m2.

 

Event-free survival (EFS) at 3 years was 68% for women and 65% in men. PFS at 3 years was also 68% for women but 74% for men. Also at 3 years, OS was 72% for women and 80% for men, according to the study data. Further, multivariable analysis showed significantly improved PFS, EFS, and OS in men receiving a higher dose, as compared with women.

 

The researchers speculate that younger men and women, who also have faster rituximab clearance rates than elderly women, may also benefit from higher rituximab doses.

 

Experts concluded that these study results should spur reevaluation of rituximab and its use in clinical practice.

Elderly Men May Need Higher Rituximab Dose for DLBCL
Elderly Men May Need Higher Rituximab Dose for DLBCL

CHICAGO ― Lesser survival seen in elderly men with diffuse large B-cell lymphoma (DLBCL) than in elderly women in response to standard therapy appears to be due to sex-related differences in the clearance rates of rituximab (Rituxan, Genentech/Roche) and could be improved by increasing the dose in older men, investigators reported at the 2014 Annual Meeting of the American Society of Clinical Oncology.

READ FULL ARTICLE From Med Scape

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs